Display options
Share it on

Oncol Rep. 1995 Sep;2(5):727-30. doi: 10.3892/or.2.5.727.

Neoadjuvant chemotherapy in locally advanced gastric-cancer - preliminary-results of a phase-ii trial with a modified famtx combination.

Oncology reports

G Facchini, A Tortoriello, F Caponigro, G Benassai, L Bucci, G Gesue, G Sarnella, D Giglio, G Persico, R Iaffaioli

Affiliations

  1. UNIV NAPLES,MED CLIN 1,I-80131 NAPLES,ITALY. UNIV CAGLIARI,IST MED INTERNA,I-09124 CAGLIARI,ITALY. IST MED LEGALE AM,I-20129 MILAN,ITALY. OSPED LORETO MARE,I-80100 NAPLES,ITALY. OSPED VECCHIO PELLEGRINI,DIV CHIRURG 3,I-80100 NAPLES,ITALY.

PMID: 21597805 DOI: 10.3892/or.2.5.727

Abstract

Twenty-two patients with locally advanced inoperable gastric cancer received neoadjuvant chemotherapy with a modified 5-fluorouracil, doxorubicin, methotrexate (FAMTX) regimen. The patients who achieved at least a stable disease were considered eligible for surgery with curative intent, which was performed in 19 cases. 16 patients (all responsive to neoadjuvant chemotherapy) were rendered disease-free by the combined approach. No treatment-related deaths occurred; grade III leukopenia was observed in only 3 cases. The preliminary results of this study indicate the feasibility of our treatment approach; randomized trials are awaited to properly evaluate the role of neoadjuvant chemotherapy in locally advanced gastric cancer.

Publication Types